10-K: OneMedNet Corporation Files 10-K, Details Financials and Business Strategy

OneMedNet Corporation's 10-K filing outlines its business model, financial performance, and future strategies in the clinical imaging and real-world data market.

Summary

• OneMedNet Corporation, a global provider of clinical imaging innovation and real-world data, filed its annual report on Form 10-K for the year ended December 31, 2023.
• The company's revenue streams include iRWD (imaging Real World Data) and BEAM, a medical imaging exchange platform.
• As of March 20, 2024, there were 23,572,232,230 shares of Common Stock outstanding.
• The company reported a net loss of $23.2 million for 2023, compared to a net loss of $6.2 million in 2022.
• The company's authorized capital stock is 101,000,000 shares, consisting of 100,000,000 shares of common stock and 1,000,000 shares of preferred stock.
• OneMedNet's long-term growth strategy focuses on increasing global reach, innovating its commercial approach, enhancing its service offering, and expanding its product portfolio.
• The company completed a business combination with Data Knights Acquisition Corp. on November 7, 2023, which resulted in Data Knights changing its name to OneMedNet Corporation.
• The global real-world evidence solutions market is projected to grow from $16.13 billion in 2023 to $36.24 billion by 2030, at a CAGR of 12.3%.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with a significant increase in net loss and a decrease in revenue. While the company has a promising business model and growth strategy, the current financial performance and risks outweigh the positives, resulting in a negative sentiment.

Positives

• OneMedNet has a growing federated network of 95+ healthcare facilities, providing a strong base for data collection.
• The company is a leader in the emerging market of regulatory-grade imaging RWD.
• OneMedNet's iRWDTM offering plays a significant role in enabling Life Science companies to bring safer and more effective patient care to market sooner.
• The company has a multi-faceted data curation process managed by an expert in-house clinical team.
• The company has a long-term growth strategy focused on expanding its global reach and product offerings.
• The company has a strong focus on regulatory compliance, including HIPAA, GDPR, and 21 CFR Part 11.

Negatives

• The company experienced a significant net loss of $23.2 million in 2023.
• Revenue decreased by 11% year-over-year.
• The company recorded a $10.5 million impairment charge related to goodwill.
• The company's cost of revenue, while reduced as a percentage of revenue, still exceeds total revenue.
• The company has a history of operating losses and may not achieve profitability in the future.
• The company's stock price may be volatile, and purchasers of the common stock could incur substantial losses.
• The company may not be able to maintain its listing on Nasdaq.

Risks

• The company has a history of operating losses and may never achieve profitability.
• The company may not be able to successfully commercialize its iRWDTM services.
• The company relies on two significant customers for a large portion of its revenue.
• The company may encounter difficulties in managing its attempted growth.
• The real-world data and real-world evidence market is highly competitive.
• The company may be unable to attract and retain key employees.
• The company's operations could be damaged by natural disasters or other catastrophic events.
• The company may not be able to raise additional capital on attractive terms.
• The company's ability to utilize net operating loss and tax credit carryforwards may be limited.
• The company is subject to many hazards and operational risks that may not be fully covered by insurance.
• The company's management has limited experience in operating a public company.
• The company may be subject to securities class action litigation.
• The company's stock price may be volatile.
• The company may not be able to maintain its listing on Nasdaq.
• The company's principal stockholders have significant influence over the company.
• The company does not expect to pay dividends in the foreseeable future.
• The company is an emerging growth company, and the reduced reporting requirements may make its stock less attractive to investors.
• Anti-takeover provisions could impair a takeover attempt.
• The company's warrants may be redeemed at a time that is disadvantageous to warrantholders.

Future Outlook

The company's long-term growth strategy is focused on increasing global reach, innovating its commercial approach, enhancing its service offering, and expanding its product portfolio. Management hopes to raise cash either through a public offering or private debt and equity offering.

Management Comments

• Management believes it has demonstrated its quality and responsiveness in clinical imaging and curation of Real-World Data.
• Management hopes to raise cash either through a public offering or private debt and equity offering.
• Management does not believe the current cash and cash equivalents are sufficient to meet foreseeable cash needs for at least the next 12 months.

Industry Context

The company operates in the growing real-world evidence solutions market, which is projected to grow significantly in the coming years. The market is driven by the increasing demand for enhanced RWE capabilities within the life science industry and the shift from volume to value-based care. The FDA's Real-World Evidence Program and the use of AI in data analysis are also contributing to market growth.

Comparison to Industry Standards

• The document references a 2016 analysis from the Tufts Center for the Study of Drug Development, which placed the cost of bringing a drug to market at $2.87 billion, highlighting the high costs and long timelines in the pharmaceutical industry.
• The document also mentions a 2018 study from the Tufts Center, noting that the timeline for new drug development ranged from 12.8 years for the average drug to 17.2 years for ultra-orphan drugs, emphasizing the need for faster treatment development.
• The document cites market projections that the global real-world evidence solutions market is projected to grow from $16.13 billion in 2023 to $36.24 billion by 2030, at a CAGR of 12.3%, indicating the high growth potential of the market.
• The document mentions that the global real-world data market is estimated to be valued at $1.59 billion in 2023 and is expected to exhibit a CAGR of 14.4% during the forecast period (2023-2030), highlighting the growth in the data segment of the market.
• The document references the FDA's framework for using Real World Evidence to support the process of drug regulation and submission, indicating the increasing acceptance of RWE by regulatory authorities.
• The document mentions the FDA's approval of Astellas drug Program (tacrolimus) for the prevention of organ rejection in lung transplant patients based on a non-interventional study providing Real-World Evidence of effectiveness, showcasing a specific example of RWE being used for regulatory approval.
• The document also mentions the approval of the supplemental BLA for Orencia to prevent graft versus host disease, which included data from a registry-based clinical study using real-world data, further demonstrating the use of RWE in regulatory approvals.

Management Changes

Corporate Governance

Legal Proceedings

• The company may be subject from time to time to various claims, lawsuits and other legal and administrative proceedings arising in the ordinary course of business.

Related Party Transactions

• The company entered into various Convertible Promissory Notes with related party investors totaling $2,300,000 in 2023.
• The company received a total of $300,000 from members of the company's Management and Directors for loan extensions.
• The company entered into a Securities Purchase Agreement in which the company was required to sell senior secured convertible notes and warrants to Directors of the company.

Stakeholder Impact

• Shareholders may experience volatility in the stock price and potential losses.
• Employees may be affected by potential cost-cutting measures or changes in the company's direction.
• Customers may be impacted by changes in the company's service offerings or pricing.
• Suppliers may be affected by changes in the company's financial stability or purchasing patterns.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended December 31, 2023.
• The company is evaluating potential actions to regain compliance with all applicable requirements for continued listing on the Nasdaq Global Market.
• The company plans to raise additional working capital through an equity or debt offering.

Key Dates

Keywords

Real-World Data, Real-World Evidence, Clinical Imaging, Healthcare Data, iRWDTM, Medical Imaging, Life Sciences, Data Curation, Regulatory Compliance, Pharmaceuticals, Medical Devices, AI, Machine Learning, HIPAA, GDPR